Full Press Release Details
regeneron provides update on phase 3 trial of fianlimab lag 3 inhibitor combination in first line unresectable or metastatic melanoma.
REGN
regeneron provides update on phase 3 trial of fianlimab lag 3 inhibitor combination in first line unresectable or metastatic melanoma
Key Takeaway: regeneron provides update on phase 3 trial of fianlimab lag 3 inhibitor combination in first line unresectable or metastatic melanoma